This is an abstract of the Plain Language Summary of Publication article.
View the full Plain Language Summary PDF of this article to read the full-text
Link to original article here
Disclosure statement
Carolina Schinke has no conflicts of interest to disclose. Cyrille Touzeau has received honoraria from BMS and is a member of a board of directors or advisory committee for BMS. Albert Oriol has received honoraria from BMS, GSK, Johnson & Johnson, Menarini, Oncopeptides, Pfizer, and Sanofi; and is a member of a board of directors or advisory committee for BMS, GSK, Johnson & Johnson, Menarini, Oncopeptides, Pfizer, and Sanofi. María-Victoria Mateos has received honoraria from AbbVie, Amgen, BMS/Celgene, GSK, Johnson & Johnson, Oncopeptides, Pfizer, Regeneron, Sanofi, Stemline, and Takeda; is a member of a board of directors or advisory committee for AbbVie, BMS/Celgene, GSK, Johnson & Johnson, Oncopeptides, Pfizer, Sanofi, Stemline, and Takeda; and is a speakers’ bureau member for Johnson & Johnson. Don Stevens has no conflicts of interest to disclose. Leo Rasche has received honoraria from BMS, GSK, Johnson & Johnson, Pfizer, Roche, and Sanofi; is a member of a board of directors or advisory committee for Amgen, BMS, Johnson & Johnson, Pfizer, and Sanofi; is a consultant for Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Sanofi; and has received research funding from BMS and Skyline Dx. Philippe Moreau has received honoraria and is a member of an advisory board for AbbVie, Amgen, BMS/Celgene, GSK, Johnson & Johnson, Pfizer, Sanofi, and Takeda. Jesús San-Miguel is a consultant and an advisory board member for AbbVie, Amgen, BMS, Celgene, GSK, HaemaLogiX, Johnson & Johnson, Karyopharm, MSD, Novartis, Regeneron, Roche, Sanofi, Secura Bio, and Takeda. Paula Rodríguez-Otero is a consultant for AbbVie, BMS, Pfizer, and Roche; is a member of a board of directors or advisory committee for AbbVie, BMS, GSK, Johnson & Johnson, Kite Pharma, Oncopeptides, Pfizer, Sanofi, and Takeda; and has received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Regeneron, Sanofi, and Takeda. Kelly Kato, Sacheeta Bathija, Eva G Katz, Tara Masterson, and Chalmer Tomlinson are employees of Johnson & Johnson and may own stock or stock options in the company. Ajai Chari is a consultant for Amgen, Antengene, BMS, Johnson & Johnson, Millenium/Takeda, and Secura Bio; and is a member of an advisory board for AbbVie, Amgen, BMS, Genentech, GSK, Johnson & Johnson, Karyopharm, Sanofi, Seattle Genetics, Secura Bio, and Shattuck Labs; and has received research funding from Amgen, BMS, Johnson & Johnson, Millenium/Takeda, and Seattle Genetics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing support was provided by Alana Dorfstatter, PharmD of Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, which was funded by Johnson & Johnson. The original authors of the full article were involved in preparing this summary.
Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work. A patient reviewer on this manuscript has disclosed they are a consultant for Regeneron, writing educational materials on multiple myeloma and their product. Patient reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Funding
This manuscript was funded by Johnson & Johnson. The funders were involved in the study design, data collection and analysis of the results, preparation of the manuscript and decision to publish.